Novo Nordisk Investigational Site
Groningen, 9728 NZ, Netherlands
NCT Number: NCT02060266
This trial is conducted in Europe. The aim of the trial is to investigate the absorption, metabolism and excretion after a single subcutaneous dose of [3H]-semaglutide in healthy male subjects.
Looking for future studies?
Notify Me45 year–64 year
Male
Interventional
Phase 1
Groningen, 9728 NZ, Netherlands
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Subjects will receive a single dose subcutaneously (s.c., under the skin).
Time frame: Up to 9 weeks following a single dose of 0.5 mg [3H]-semaglutide
Time frame: Up to 9 weeks following a single dose of 0.5 mg [3H]-semaglutide
Time frame: Up to 9 weeks following a single dose of 0.5 mg [3H]-semaglutide
Time frame: Up to 9 weeks following a single dose of 0.5 mg [3H]-semaglutide
Time frame: From time 0 until infinity after a single dose
Time frame: After a single dose
Novo Nordisk A/S
Industry
A Single Centre, Open Label Trial Investigating the Absorption, Metabolism and Excretion After a Single Subcutaneous Dose of [3H]-Semaglutide in Healthy Male Subjects
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05970601
Diabetes, Diabetes Mellitus
Düsseldorf, Germany
View Trial DetailsNCT01508897
Diabetes, Diabetes Mellitus
Neu-Ulm, Germany
View Trial DetailsNCT01507285
Diabetes, Diabetes Mellitus
Manchester, United Kingdom
View Trial DetailsNCT03983733
Behavior, Behavior, Animal
Boston, Massachusetts, United States
View Trial Details